Esperion Therapeutics, Inc. (ESPR) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Esperion Therapeutics, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -33.91x | -7.96x | -1.47x | -1.77x | -0.54x | -4.98x |
| P/B Ratio | -2.55x | -1.06x | -0.68x | -1.28x | -0.73x | -7.43x |
| P/S Ratio | 1.91x | 1.24x | 2.65x | 5.48x | 1.84x | 3.14x |
| Profitability | ||||||
| Gross Margin | 67.9% | 79.4% | 62.8% | 64.3% | 81.9% | 98.9% |
| Operating Margin | 15.0% | 16.4% | -133.7% | -237.8% | -289.0% | -53.3% |
| Net Margin | -5.6% | -15.6% | -179.9% | -309.6% | -343.0% | -63.1% |
| EBITDA Margin | 15.0% | 2.3% | -129.0% | -233.7% | -283.2% | -52.9% |
| Liquidity | ||||||
| Current Ratio | 0.56x | 1.37x | 1.29x | 2.67x | 4.48x | 3.68x |
| Quick Ratio | 0.21x | 0.99x | 0.87x | 2.29x | 4.02x | 3.51x |
| Leverage | ||||||
| Debt/Equity | -1.81x | -1.52x | -1.19x | -0.81x | -1.32x | -1.93x |
YoY = year-over-year change. Source: FMP..